Combination Therapy of Cyclosporine a with Methotrexate or Hydroxychloroquine in Refractory Rheumatoid Arthritis

References

• Wolfe F, Hawley D J, Cathey M A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994–1002
   PubMed Web of Science ®Google Scholar
• Weinblatt M E, Weissman B N, Holdsworth D E, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-months update. Arthritis Rheum 1992; 35: 129–37
   PubMed Web of Science ®Google Scholar
• Kremer J. M, Phelps C T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35: 138–45
   PubMed Web of Science ®Google Scholar
• Salaffl F, Carotti M, Sartini A, Cervini C. A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 23–8
   PubMedGoogle Scholar
• Situnayake R D, Grindulis K A, McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold or penicillamine: a comparison using life-table methods. Ann Rheum Dis 1987; 46: 177–83
   PubMed Web of Science ®Google Scholar
• Ferraccioli G F, Salaffi F, Nervetti A, Manganelli P. Long-term outcome with gold thiosulphate and tiopronin in 200 rheumatoid patients. Clin Exp Rheumatol 1989; 7: 1–5
   PubMedGoogle Scholar
• Pincus T, Marcum S B, Callahan L F. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. Second-line drugs and prednisone. J Rheumatol 1992; 19: 1885–94
   PubMed Web of Science ®Google Scholar
• Primer on the Rheumatic Diseases, 9th Ed, H R Schumaker, Jr. Arthritis Foundation, Atlanta, GA 1988; 93–9
   Google Scholar
• Wilske K R, Healey L A. Remodelling the pyramid - a concept whose time has come. J Rheumatol 1989; 16: 565–7
   PubMed Web of Science ®Google Scholar
• Fries J F. Reevaluating the therapeutic approach to rheumatoid arthritis: the “Sawtooth” strategy. J Rheumatol 1990; 17(Suppl 17)22–5
   Google Scholar
• Wilke W S, Clough J D. Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 1991; 21(Suppl 1)21–34
   PubMed Web of Science ®Google Scholar
• Bensen W G, Bensen W, Adachi J D, Tugwell P X. Remodelling the pyramid: the therapeutic target of rheumatoid arthritis. J Rheumatol 1990; 17: 987–9
   PubMed Web of Science ®Google Scholar
• Wilske K R, Healey L A. Challenge the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol 1990; 17(Suppl 25)4–7
   Google Scholar
• McCarty D J. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J Rheumatol 1990; 17: 1115–8
   PubMed Web of Science ®Google Scholar
• Boers M, Ramsden M. Long-acting drug combinations in RA: a formal overview. J Rheumatol 1991; 18: 316–24
   PubMed Web of Science ®Google Scholar
• Felson D T, Anderson J J, Meenan R F. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A metaanalysis. Arhritis Rheum 1994; 37: 1487–91
   PubMed Web of Science ®Google Scholar
• McCarty D J, Carrera G F. Intractable rheumatoid arthritis: treatment with combined cyclophosphamide, azathioprine and hydroxychloroquine. JAMA 1982; 248: 1718–23
   PubMed Web of Science ®Google Scholar
• Csuka M E, Carrera G F, McCarty D F. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydroxychloroquine: a follow up study. JAMA 1986; 255: 2315–9
   PubMed Web of Science ®Google Scholar
• Paulus H E. Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs. Am J Med 1988; 85(Suppl 4A)45–52
   PubMedGoogle Scholar
• Paulus H E. Current controversies in rheumatology: the use of drug disease modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990; 33: 113–20
   PubMed Web of Science ®Google Scholar
• Kronke M, Leonard W J, Depper J M, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1983; 81: 5214–8
   Google Scholar
• Russel R GG, Graveley R, Coxon F, et al. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand J Rheumatol 1992; 21(Suppl 95)9–18
   Google Scholar
• Kaibara N, Hotokebuchi T, Takasashi K, Katsuki I. Paradoxical effects of cyclosporine A on collagen arthritis in rats. J Exp Med 1983; 158: 2007–15
   PubMed Web of Science ®Google Scholar
• Henderson B. The anti-arthritic and immunosuppressive effects of cyclosporine on arthritis induced in the rat by type II collagen. Clin Exp Immunol 1984; 57: 51–6
   PubMed Web of Science ®Google Scholar
• Yocum D E, Allen J B, Wahl S M, Calandra G B, Wilder R L. Inhibition by cyclosporine A of streptococcal cell wall-induced arthritis in rats. Arthritis Rheum 1986; 29: 262–73
   PubMedGoogle Scholar
• Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988; 47: 127–33
   PubMed Web of Science ®Google Scholar
• Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051–5
   PubMed Web of Science ®Google Scholar
• van Rijthoven A WAM, Dijkmans B AC, Goei The H S, et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double-blind, multicentre study. J Rheumatol 1991; 18: 815–20
   PubMed Web of Science ®Google Scholar
• Madhok R, Torley H I, Capell H A. A study of the long-term efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 1991; 18: 1485–9
   PubMed Web of Science ®Google Scholar
• Landewe R BM, Goei The H S, van Rijthoven A WAM, Rietveld J R, Breedveld F C, Dijkmans B AC. Cyclosporine in common clinical practice: an estimation of the benefit/ risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994; 21: 1631–6
   PubMedGoogle Scholar
• Landewé R BM, Goei The H S, van Rijthoven A WAM, Breedveld F C, Dijkmans B AC. A randomized, double-blind, 24-week controlled study of low dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37: 637–43
   PubMed Web of Science ®Google Scholar
• Kriiger K, Schattenkirchner M. Comparison of cyclosporine A and azathioprine in the treatment of rheumatoid arthritis. Results of a double-blind multicentre study. Clin Rheumatol 1994; 13: 248–55
   PubMedGoogle Scholar
• Førre Ø, Bjerkhoel F, Salvesen C F, et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987; 30: 88–92
   PubMed Web of Science ®Google Scholar
• Bensen W, Tugwell P, Roberts R M, et al. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994; 21: 2034–8
   PubMedGoogle Scholar
• Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Eng J Med 1995; 333: 137–41
   PubMed Web of Science ®Google Scholar
• Yocum D E, Cornett M, Olson S, Nordensson K. Effects of methotrexate and methotrexate + cyclosporine on mononuclear cell proliferation and lymphocyte surface markers in rheumatoid arthritis patients: results of a double-blind trial. Arthritis Rheum 1994; 37(Suppl 9)S254
   Google Scholar
• Stein C M, Pinus T, Brooks R H, et al. Combination therapy with cyclosporine and methotrexate: results of a 24-week extension study subsequent to a 24-week double-blind study. Arthritis Rheum 1994; 37(Suppl 9)S252
   Google Scholar
• Brahn E, Peacock D, Banquerigo M. Suppression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy. Arthritis Rheum 1991; 34: 1282–8
   PubMedGoogle Scholar
• Cervini C, Grassi W. Treatment of rheumatoid arthritis: our experience. Clin Exp Rheumatol. 1989; 7(Suppl 3)187–93
   Google Scholar
• Felson D T, Anderson J J, Meenan R F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33: 1449–59
   PubMed Web of Science ®Google Scholar
• Dijkmans B AC, de Vries E, Vreede T M, Cas A. Effects of anti-rheumatic drugs on in vitro mitogenic stimulation of peripheral blood mononuclear cells. Transplant Proceed 1988; 2(Suppl 2)253–8
   Google Scholar
• Dijkmans B AC, De Vries E, De Vreede T M. Synergistic and additive effects of disease modifying antirheumatic drugs combined with chloroquine on the mitogen-driven stimulation of mononuclear cells. Clin Exp Rheumatol 1990; 8: 455–9
   PubMedGoogle Scholar
• Landewe R BM, Miltenburg A MM, Breedveld F C, Daha M R, Dijkmann B AC. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353–7
   PubMed Web of Science ®Google Scholar
• Arnett F C, Edworthy S M, Bloch D A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger C H, Batterman R C. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659–62
   PubMed Web of Science ®Google Scholar
• Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Ritchie D M, Boyle J A, McLnnes J M, Grieveson P, Buchanan W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: 393–406
   PubMedGoogle Scholar
• Fries J F, Spits P, Kraines R G, Holman H R. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• Carotti M, Salaffi F, Ferraccioli G F, Binci M, Sartini C. A, Cervini C. Soluble interleukin-2 receptor in sera and synovial fluids of rheumatoid patients: correlations with disease activity. Rheumatol Int 1994; 14: 47–52
   PubMedGoogle Scholar
• Ferraccioli G F, Salaffi F, Troise-Rioda W, Bartoli E. The Chronic Arthritis Systemic Index. Clin Exp Rheumatol 1994; 12: 241–7
   PubMedGoogle Scholar
• Ferraccioli G F, Bartoli E, Salaffi F, Peroni M. Chronic arthritis systemic index (CASI): a nomogram to assess activity and severity of chronic arthritis. Arthritis Rheum 1993; 36: 1180–1
   PubMedGoogle Scholar
• Fuchs H A, Kaye J J, Callahan L F, Nance E P, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585–91
   PubMed Web of Science ®Google Scholar
• Salaffi F, Ferraccioli G F, Peroni M, Carotti M, Bartoli E, Cervini C. Progression of erosion and joint space narrowing scores in rheumatoid arthritis assessed by nonlinear models. J Rheumatol 1994; 21: 1626–30
   PubMedGoogle Scholar
• Boers M, Dukmans B AC, van Rijthoven A WAM, Goei The H S, Cats A. Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol 1900; 17: 38–42
   Google Scholar
• Førre Ø and Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multic-enter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994; 10: 1506–12
   Google Scholar